Interstitial lung disease patients live on a different oxygen-demand trajectory from COPD patients. The same numeric saturation thresholds — PaO₂ ≤55 mmHg, SpO₂ ≤88% — qualify them for LTOT, but the disease progresses faster, exertional desaturation is steeper, and the flows required during activity are often beyond what a 5 LPM concentrator can deliver. This article walks through how to prescribe oxygen for ILD, why the resting ABG often underestimates the functional requirement, and what equipment selections actually work for a patient who desaturates to SpO₂ 80% on a 6-minute walk test.
The audience is the pulmonologist or respiratory therapist managing ILD, the home-care dealer specifying equipment for a new ILD prescription, and families trying to understand why the oxygen need keeps climbing.
The ILD spectrum and why it matters for oxygen prescribing
ILD is not one disease. The oxygen-therapy implications diverge meaningfully across the major categories.
Idiopathic pulmonary fibrosis (IPF). Median survival without antifibrotic therapy is 3–5 years from diagnosis. With pirfenidone or nintedanib, decline slows but does not stop. The archetypal IPF oxygen trajectory: resting PaO₂ normal at diagnosis, exertional desaturation appearing 1–2 years in, resting hypoxaemia 2–4 years in, rapid escalation in the final 6–12 months (ATS/ERS statement).
Non-specific interstitial pneumonia (NSIP). More indolent than IPF in most cases. Fibrotic NSIP behaves similarly to IPF; cellular NSIP often responds to immunosuppression with saturation improvement. Oxygen prescribing should reassess at 6-month intervals because some NSIP patients improve.
Sarcoidosis. A bimodal picture — the majority of Indian patients with sarcoidosis do not progress to fibrotic sarcoidosis, but the subgroup that does can have severe lung restriction and oxygen requirement. The airway-predominant subtype may also have exertional desaturation disproportionate to imaging.
Hypersensitivity pneumonitis (HP). Acute HP (farmer’s lung, bird-fancier’s lung, and in Indian urban settings, indoor-mould exposure from coastal humidity or cold-climate housing) may resolve with antigen avoidance and steroids. Chronic fibrotic HP behaves like IPF and shares the trajectory and equipment needs.
Connective-tissue-disease-associated ILD (CTD-ILD). Commonly seen with scleroderma, rheumatoid arthritis, polymyositis/dermatomyositis, mixed connective tissue disease. Disease course depends on the underlying CTD. Some CTD-ILD is responsive to immunosuppression with oxygen-need stabilisation or reduction.
The common thread for oxygen prescribing: ILD patients tend to desaturate sharply on exertion — more sharply than COPD patients at the same resting SpO₂ — and the disease trajectory is measured in months, not years.
Oxygen prescription thresholds
The numeric LTOT thresholds are the same as for COPD (GOLD Report):
- PaO₂ ≤55 mmHg (SaO₂ ≤88%) at rest on room air, in a stable patient — unambiguous LTOT indication.
- PaO₂ 55–60 mmHg with cor pulmonale, polycythaemia, or pulmonary hypertension — LTOT indicated.
- PaO₂ > 60 mmHg at rest but significant exertional desaturation (SpO₂ ≤88% during 6MWT) — ambulatory oxygen indicated, even though continuous LTOT evidence is weaker.
The ILD-specific modifier: exertional desaturation assessment is not optional. The 6MWT is a required part of ILD workup, and a significant fraction of ILD patients with “normal” resting SpO₂ will desaturate severely on walking. Prescribing oxygen for ILD without a 6MWT means prescribing blind to the functional oxygen requirement.
Why ILD patients desaturate more steeply
Two mechanisms dominate.
First, diffusion limitation. The fibrotic interstitium thickens the alveolar-capillary barrier. At rest, the red cell has adequate transit time (~0.75 sec) to fully saturate. During exercise, cardiac output rises, transit time shortens (to ~0.25 sec in high-intensity exercise), and the diffusion barrier that was clinically invisible at rest becomes limiting. The patient desaturates steeply.
Second, ventilation-perfusion mismatch that worsens with exercise. Fibrotic lung has heterogeneous regional compliance; some zones ventilate, some perfuse, and on exertion the mismatch amplifies.
The clinical consequence: an ILD patient with resting SpO₂ 94% may drop to 80% or lower on a 6MWT. At that level of desaturation, the required FiO₂ to maintain acceptable saturation can exceed what 5 L/min nasal cannula can deliver in a tachypnoeic patient. Equipment selection follows.
PFT integration
The PFT profile in ILD is restrictive — reduced TLC, FVC, FEV1 proportional to FVC (FEV1/FVC preserved), and — critically — reduced DLCO. DLCO tracks oxygen-transfer capacity and is the single best PFT predictor of exertional desaturation. A patient with DLCO < 40% predicted is likely to desaturate on 6MWT even if resting spirometry looks only mildly abnormal.
Serial PFTs in ILD serve multiple purposes:
- FVC trend tracks disease progression and anti-fibrotic response (pirfenidone, nintedanib).
- DLCO trend tracks oxygen-transfer loss and predicts oxygen-need escalation.
- 6MWT desaturation nadir is the practical functional metric for oxygen prescription.
The prescribing cadence in a stable ILD patient: PFT every 3–6 months, 6MWT at each PFT visit, oxygen prescription reviewed against measured saturation rather than family report.
Equipment selection — where ILD breaks 5 LPM
The 5 LPM stationary concentrator is the workhorse for most Indian LTOT prescriptions. For ILD patients past the early stages, it is often not enough.
Resting flow. A patient titrated at rest to SpO₂ 88–92% on 2 L/min is served by a 5 LPM concentrator. This is typical early-disease prescription.
Exertional flow. On a 6MWT, the same patient may need 4–6 L/min to maintain SpO₂ ≥ 88%. A 5 LPM concentrator is at its ceiling at 5; a tachypnoeic patient with a high inspiratory flow demand dilutes the cannula delivery with room air, and the delivered FiO₂ at the airway is less than the nominal cannula setting suggests.
Later-disease flow. Advancing IPF and fibrotic HP patients routinely need 6–10 L/min during activity and sometimes 4–6 L/min at rest. A 10 LPM concentrator becomes necessary. 10 LPM units — Drive DeVilbiss 10L, Respironics Millennium M10, Oxymed 10L, the Home Medix HM-KX 10 LPM — offer the headroom.
Very-late-disease flow. Some end-stage ILD patients need 15+ LPM, which exceeds any single concentrator. Options: (a) two 10 LPM concentrators teed together — a Y-connector with careful flowmeter matching — (b) liquid oxygen, available in Indian tertiary centres but not at home, (c) cylinder-based high-flow setups as a bridge.
The cannula versus mask decision also shifts in ILD. Above 6 L/min, nasal cannula starts to be uncomfortable (dry mucosa, crusting) and the FiO₂ plateau is reached. A simple mask at 6–10 L/min, a Venturi at specific FiO₂ settings, or a non-rebreather at 10–15 L/min each have a place. See our interface-selection guide for specifics.
Pulse-dose portable concentrators in ILD
The appeal of a pulse-dose portable — Inogen One G4 (1–3 kg), Inogen One G5, Philips SimplyGo Mini, CAIRE FreeStyle Comfort — is battery life and weight. The failure mode in ILD: pulse-dose delivers a bolus triggered on inspiration. The effective oxygen minute-delivery at “setting 3” on a pulse-dose unit is substantially less than 3 LPM continuous. Patients with high respiratory rates, shallow breathing, or mouth-breathing — all common in advancing ILD — under-trigger the device or receive insufficient bolus volume. Saturation falls despite the displayed setting.
Practical guidance: if a 6MWT on pulse-dose setting 5 (the typical ceiling) cannot maintain SpO₂ ≥ 88%, the patient is not a pulse-dose candidate. Continuous-flow portables — SimplyGo (not Mini), Respironics EverGo, SeQual Eclipse 5, the Oxymed 3L continuous — are heavier (4–6 kg) and have shorter battery life but deliver predictable flow that works for tachypnoeic or mouth-breathing patients.
For severe desaturators (nadir SpO₂ < 80% on 6MWT), even continuous portables in the 3–5 LPM range may be inadequate. Cylinder-based ambulation with a pulse-dose regulator remains the fallback; liquid oxygen, where regionally available, is the gold standard but unavailable in most Indian home markets.
Concurrent antifibrotic therapy — pirfenidone and nintedanib
Both pirfenidone and nintedanib slow FVC decline and, by extension, slow the oxygen-need escalation trajectory. Neither reverses established hypoxaemia. The drug-oxygen interaction points to be aware of:
Pirfenidone causes photosensitivity in many patients. An ILD patient spending more time outdoors on ambulatory oxygen should be counselled on sun protection. GI side effects (nausea, diarrhoea) can reduce adherence.
Nintedanib causes diarrhoea in a significant fraction and is associated with liver enzyme elevation. Nintedanib does not have the photosensitivity issue.
Neither drug meaningfully alters oxygen titration. A patient on pirfenidone who has stabilised on LTOT at 3 L/min does not have the flow reduced on the basis of drug therapy alone; titration is to measured saturation.
Indian-specific considerations
Altitude. ILD patients at Indian hill stations — Shimla, Darjeeling, Gangtok, Ooty — have lower baseline PaO₂ than sea-level equivalents. Oxygen need is higher at altitude and the equipment must accommodate the flow. Concentrators also derate at altitude; a 10 LPM unit specified at sea level delivers lower purity and flow at Shimla (2200 m) or Leh (3500 m). Consult manufacturer derating tables or the altitude-specific guidance.
Voltage and mains stability. A 10 LPM concentrator draws 600–750 W. Indian mains voltage variance (160–260V in tier-2/3 cities) stresses the compressor. A voltage stabiliser sized for the startup surge (1.5 kVA for a 10 LPM unit) is part of the equipment list, not optional.
Service network. 10 LPM units are less common in the Indian dealer network than 5 LPM units. Parts availability for a 10L Respironics or Drive DeVilbiss is adequate in metros and weakening in tier-3 cities. Oxymed and BPL 10L units have broader provincial dealer networks. For an advancing IPF patient in a smaller town, dealer service reach should influence brand selection more than spec comparisons.
Cost. A 5 LPM concentrator in India runs ₹40,000–70,000 depending on brand; a 10 LPM unit runs ₹80,000–1,40,000. Monthly electricity at 15+ hours/day on a 10 LPM unit is ₹4,000–8,000 in high-tariff states. Rental options exist in most metros (₹8,000–15,000/month for a 10 LPM unit with service included) and often make sense for finite-duration use or when the patient is approaching end of life.
Palliative-care framing. Advancing IPF is a terminal diagnosis. Oxygen prescribing in late-stage ILD is partly symptom management and partly life-extension. Families often expect the oxygen to “cure” and are distressed when saturation continues to fall despite the device. An honest conversation at prescription — this device buys comfort and function, not reversal — is part of the prescription.
Practical titration patterns in ILD
A suggested titration approach for a newly diagnosed ILD patient qualifying for oxygen:
-
Establish resting requirement. Room-air SpO₂ at rest, seated, after 10 minutes of quiet breathing. If resting SpO₂ < 88%, begin at 2 LPM cannula and titrate upward in 0.5–1 LPM increments until SpO₂ sits 90–93%. Many ILD patients need 3–4 LPM at rest by mid-disease.
-
Establish exertional requirement. A 6MWT with the patient on their resting flow setting. If saturation falls below 88% on the 6MWT, retest at a higher flow (add 1–2 LPM). Record the flow at which the patient maintains SpO₂ ≥ 88% throughout the test. This is the ambulatory prescription.
-
Establish nocturnal requirement. Overnight pulse oximetry on the resting flow for 2 nights. If the patient has sustained desaturation < 88% during sleep, titrate nocturnal flow upward or consider nocturnal NIV (BiPAP) if CO₂ retention contributes.
-
Document three settings separately. Resting, exertional, nocturnal. Communicate these to the home-care dealer and the family so that the concentrator flow is adjusted for the activity, not left at a single default value.
-
Reassess every 3–6 months. ILD oxygen needs escalate. A prescription written six months ago is likely to be inadequate today.
A trap in Indian practice: writing one flow rate for “oxygen” without distinguishing rest, exertion, and sleep. The patient sits at the resting flow during exertion and desaturates; the family escalates the flow anxiously and over-delivers at rest. Prescribe three settings, train the family to use them.
The pulmonary-hypertension overlap
Some ILD patients develop secondary pulmonary hypertension (PH-ILD). Oxygen prescribing in PH-ILD is slightly different — the target saturation rises (≥ 92% rather than ≥ 88%) because reduced oxygen even at SpO₂ 88–92% amplifies pulmonary vasoconstriction and worsens RV load. An echo showing estimated PASP > 45 mmHg in an ILD patient should shift the oxygen target upward and may warrant addition of PH-specific therapy in a specialised centre.
Clinical takeaway
ILD patients qualify for LTOT on the same numeric thresholds as COPD but escalate faster, desaturate more steeply on exertion, and often outgrow 5 LPM equipment within 12–24 months. Prescribe with a documented 6MWT and DLCO, not on resting SpO₂ alone. Plan equipment selection for the trajectory — a 10 LPM concentrator and a continuous-flow portable are often justified from mid-disease onward, and pulse-dose portables fail reliably in severe desaturators. Reassess saturation, flow, and equipment adequacy every 3–6 months.
Consult your pulmonologist before changing oxygen therapy; ILD oxygen needs change rapidly and the correct flow today is often not the correct flow in six months.